TITLE

Finally a warning

PUB. DATE
June 2007
SOURCE
New Scientist;6/16/2007, Vol. 194 Issue 2608, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article announces that the U.S. Food and Drug Administration (FDA) will add a more drastic warning label to the diabetes drug Avandia, created by GlaxoSmithKline. Drug makers who push for speedy approvals of new products often disregard the rushed studies of scientists and side effects are not always correctly documented and important warnings are not addressed.
ACCESSION #
27199219

 

Related Articles

  • Promacta safety warning.  // Monthly Prescribing Reference;Jun2010, Vol. 26 Issue 6, pA.18 

    The article reports on the warning given by the Food and Drug Administration (FDA) and GlaxoSmithKline to healthcare professionals on the development of thrombocytopenia in patients with chronic liver diseases treated with eltromobopag tablets Promacta in the U.S.

  • As I See It. Dickinson, James G. // Medical Marketing & Media;Nov2010, Vol. 45 Issue 11, p30 

    In this article, the author comments on the issue concerning the credibility of the U.S. Food and Drug Administration's (FDA) traditional internal secrecy after the agency released the uncertain risks of the Avandia drug from GlaxoSmithKline. According to the author, the FDA needs to present...

  • Avandia, Risk of Congestive Heart Failure Significant Safety Risk.  // Neurology Alert;Jul2007, Vol. 25 Issue 11, p1 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to issue a black box warning to the rosiglitazone drug Avandia and the pioglitazone drug Actos manufactured by GlaxoSmithKline due to concerns over health failure associated with the use of the drugs. The...

  • Avandia, Risk of Congestive Heart Failure Significant Safety Risk. Elliott, William T. // Clinical Oncology Alert;Jul2007 Pharmacology Watch, p1 

    The article reports on a black box warning that will be issued by the U.S. Food and Drug Administration (FDA) to the rosiglitazone (Avandia) drug of GlaxoSmithKline. The warning will be issued due to concerns over heart failure associated with the use of the drug. A trial was conducted to...

  • Avandia, Risk of Congestive Heart Failure Significant Safety Risk. Elliott, William T. // Clinical Cardiology Alert;Jul2007 Pharmacology Watch, p1 

    The article reports on a black box warning that will be receive by GlaxoSmithKline's rosiglitazone (Avandia) from the U.S. Food & Drug Administration (FDA) because of concerns over heart failure associated with use of the drug. The other drug that will be subjected to a black box warning is...

  • FDA reviews TZD safety.  // OB/GYN Clinical Alert;Apr2010 Pharmacology, p1 

    The article reports on the review of the data on the safety of GlaxoSmithKline's thiazolidinediones (TZD) by the Food and Drug Administration (FDA) in the U.S. Moreover, FDA is planning a public meeting in July 2010 to present all known heart-related safety data on the drug . It states that some...

  • FDA's Graham Fires More Cardio Risk Bullets at Avandia. Young, Donna // BioWorld Today;6/30/2010, Vol. 21 Issue 125, p1 

    The article reports on the insistence of David Graham, associate director for science and medicine at the U.S. Food and Drug Administration's (FDA) Office of Surveillance and Epidemiology, to remove pharmaceutical company GlaxoSmithKline PLC's (GSK) Type II diabetes drug Avandia from the U.S....

  • FDA: Avandia poses "potential safety issue".  // Fire Engineering;Sep2007, Vol. 160 Issue 9, p51 

    The author reports that the U.S. Food and Drug Administration (FDA) has warned of an increase in the risk of heart related diseases of patients who take the medication Avandia. According to the article, clinical trials which have been done on Avandia have not found an elevated risk. The article...

  • FDA advisory panels recommend Lotronex be put back on market. Charatan, Fred // BMJ: British Medical Journal (International Edition);5/4/2002, Vol. 324 Issue 7345, p1053 

    Reports that two advisory committees of the U.S. Food and Drug Administration (FDA) have recommended that alosetron hydrochloride (Lotronex), voluntarily withdrawn in November 2000 by GlaxoSmithKline, should be put back on the market. Process of application to the FDA by GlaxoSmithKline to...

  • FDA advisers recommend easing Avandia restrictions.  // Drug Topics;Jul2013, Vol. 157 Issue 7, p33 

    The article reports on the recommendation of the Food and Drug Administration (FDA) advisers on the easing of restrictions on Avandia in the U.S. It notes that the easing of restrictions on the diabetes drug rosiglitazone was recommended by FDA advisers after concerns were raised following an...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics